Loqtorzi Side Effects
Generic name: toripalimab
Medically reviewed by Drugs.com. Last updated on Jan 13, 2024.
Note: This document contains side effect information about toripalimab. Some dosage forms listed on this page may not apply to the brand name Loqtorzi.
Applies to toripalimab: intravenous solution.
Warning
Toripalimab causes your immune system to attack tumor cells, but it could also attack healthy organs and tissues in your body. This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal gland during or after using this medicine.
Call your doctor at once if you have: skin problems, vision problems, fever, swollen glands, neck stiffness, chest pain, cough, shortness of breath, muscle or joint pain, pale skin, weakness, diarrhea, severe stomach pain, blood in your stools, bruising or bleeding, yellowing of the skin or eyes, a hormonal disorder, or a change in the amount or color of your urine.
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include skin rash, skin sores, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.
Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.
Toripalimab (the active ingredient contained in Loqtorzi) causes your immune system to attack tumor cells, but it could also attack healthy organs and tissues in your body. This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal glands.
Call your doctor at once if you have:
-
intestinal problems--severe stomach pain, diarrhea, bloody or tarry stools;
-
liver problems--loss of appetite, nausea, vomiting, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
-
immune system problems--confusion, problems with thinking or memory, balance problems, trouble breathing, weakness, muscle cramps, irregular heart rhythm or swelling of ankles;
-
signs of organ transplant rejection--feeling sick or uneasy, with pain or swelling near your transplanted organ;
-
signs of a hormonal disorder--unusual headaches, vision problems, feeling light-headed, rapid heartbeats, mood or behavior changes, hoarse or deepened voice, increased hunger or thirst, increased urination, constipation, hair loss, sweating, feeling cold, weight gain, or weight loss;
-
lung problems--cough, shortness of breath, chest pain;
-
kidney problems--swelling, urinating less, feeling tired or short of breath; or
-
low red blood cells (anemia)--pale skin, tiredness, feeling light-headed, cold hands and feet.
Your treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
-
nausea, vomiting, loss of appetite;
-
diarrhea, constipation;
-
fever, cough, cold symptoms such as stuffy nose, sneezing, sore throat;
-
dizziness;
-
feeling very weak or tired;
-
low levels of thyroid hormone;
-
rash;
-
numbness or tingling in your feet;
-
muscle or bone pain; or
-
sleep problems (insomnia).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to toripalimab: intravenous solution.
General
The most common adverse reactions of 20% or greater frequency were nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, fatigue, dizziness, and malaise.
Cardiovascular
Common (1% to 10%): Hypertension
Frequency Not Reported: Myocarditis, pericarditis, pericardial effusion, vasculitis[Ref]
Hypertension included blood pressure increased, blood pressure systolic increased, hypertension, and hypertensive crisis.[Ref]
Dermatologic
Very common (10% or more): Rash (up to 36%), pruritus (up to 17%)
Rash included acneiform dermatitis, allergic dermatitis, catheter-site rash, dermatitis, drug eruption, eczema, erythema, macule, maculopapular rash, palmar-plantar erythrodysesthesia syndrome, papule, pruritic rash, rash, and urticaria.
Endocrine
Very common (10% or more): Hypothyroidism (up to 38%)
Frequency Not Reported: Hypoparathyroidism
Hypothyroidism included hypothyroidism, tri-iodothyronine decreased, tri-iodothyronine free decreased, and thyroiditis.
Gastrointestinal
Very common (10% or more): Nausea (up to 71%), vomiting (up to 68%), constipation (up to 39%), diarrhea (up to 31%), stomatitis (up to 12%)
Frequency Not Reported: Duodenitis, gastritis, pancreatitis
Stomatitis included mouth ulceration, stomatitis, and radiation stomatitis. Pancreatitis included increases in serum amylase and lipase levels.
Hematologic
Very common (10% or more): Decreased hemoglobin (up to 94%), decreased neutrophils (up to 91%), decreased lymphocytes (up to 88%), decreased platelets (up to 71%)
Common (1% to 10%): Epistaxis
Frequency Not Reported: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection
Metabolic
Very common (10% or more): Decreased magnesium (up to 78%), decreased sodium (up to 63%), increased ALT (up to 58%), increased AST (up to 58%), decreased appetite (up to 55%), decreased albumin (up to 49%), decreased calcium (up to 45%), increased LDH (up to 42%), increased calcium (up to 39%), decreased potassium (up to 40%), increased creatinine (up to 39%), increased alkaline phosphatase (up to 27%), increased triglyceride (26%), decreased glucose (up to 23%), decreased weight (11%)
Musculoskeletal
Very common (10% or more): Musculoskeletal pain (up to 25%)
Frequency Not Reported: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis
Musculoskeletal pain included back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity, pain in jaw.
Nervous system
Peripheral neuropathy includes hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy.
Very common (10% or more): Peripheral neuropathy (up to 30%), dizziness (up to 21%), headache (up to 18%)
Frequency Not Reported: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
Other
Fatigue included asthenia and fatigue.
Very common (10% or more): Pyrexia (up to 32%), malaise (up to 21%), fatigue (up to 19%; includes asthenia and fatigue)
Psychiatric
Very common (10% or more): Insomnia (up to 23%)
Respiratory
Very common (10% or more): Cough (up to 26%), upper respiratory infection (up to 23%), pneumonia (up to 18%)
Cough included cough and productive cough. Upper respiratory infection included acute sinusitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, and upper respiratory tract infection. Pneumonia included aspiration pneumonia and pneumonia.
Frequently asked questions
- What are monoclonal antibodies?
- What is the MOA of Loqtorzi (toripalimab)?
- How does Loqtorzi work for nasopharyngeal carcinoma?
- How Accurate is Screening for Nasopharyngeal Carcinoma?
More about Loqtorzi (toripalimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Loqtorzi (toripalimab). Coherus BioSciences, Inc. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.